Skip to main content

Table 3 Characteristics of patients enrolled before and after the study protocol amendment

From: Phase II trial of neoadjuvant pemetrexed plus cisplatin followed by surgery and radiation in the treatment of pleural mesothelioma

   Before PAa After PA All
N Gender, n (%)   21 33 54
  Male 17 (81.0) 30 (90.9) 47 (87.0)
  Female 4 (19.0) 3 (9.1) 7 (13.0)
Age (yrs) Median (range)   61.0 (39–71) 64.0 (44–75) 63.0 (39–75)
Race, n (%)     
  Caucasian 21 (100.0) 33 (100.0) 54 (100.0)
Clinical Staging, n (%)     
  I (T1,N0,M0) 1 (4.8) 11 (33.3) 12 (22.2)
  II (T2,N0,M0) 2 (9.5) 7 (21.2) 9 (16.7)
  III (T3,N1-2 M0) 17 (81.0) 16 (48.5) 33 (61.1)
Histology,n (%)     
  Epithelial 18 (85.7) 30 (90.9) 48 (88.9)
  Biphasic 2 (9.5) 1 (3.0) 3 (5.6)
  Desmoplastic 1 (4.8) 2 (6.1) 3 (5.6)
  1. a Protocol Amendment
  2. Data are presented stratified by time of enrollment in this study with respect to the protocol amendment and are expressed as number of patients (percentage) except for age, expressed as mean (SD).